Erythropoietin (EPO) vs Melanotan II
Extensively Studied vs Well Studied
monitor Mechanism-based · 51% Both Erythropoietin (EPO) and Melanotan II can raise blood pressure. Monitor BP regularly and consider adding cardiovascular support (cardarine, telmisartan, or similar).
Molecular Data
Erythropoietin (EPO) Melanotan II
Weight 30,400 Da —
Half-life 4-12 hours (IV), ~25 hours (SubQ) ~2 hours
Chain 165 amino acids —
Type Glycoprotein hormone Synthetic alpha-MSH analog
Key Benefits
Erythropoietin (EPO)
01 Stimulates red blood cell production
02 Increases oxygen-carrying capacity
03 FDA-approved for anemia treatment
04 Improves endurance capacity
05 Supports patients with chronic kidney disease
06 Helps chemotherapy-induced anemia
07 Well-characterized mechanism of action
08 Extensively studied safety profile
Melanotan II
01 Rapid tanning without UV exposure
02 Enhanced sexual function and libido
03 Appetite suppression
04 Improved mood via melanocortin activation
05 Photoprotection through increased melanin
Dosing Protocols
Erythropoietin (EPO)
50-300 IU/kg based on medical indication / 1-3 times weekly depending on response
CKD Anemia (medical) 50-100 IU/kg 3x weekly
Chemotherapy Anemia (medical) 150-300 IU/kg 3x weekly
Maintenance (medical) Individualized 1-3x weekly
Melanotan II
Loading: Start 0.25mg daily, increase to 0.5-1mg; Maintenance: 0.5-1mg 2-3x weekly / Loading phase: Daily for first week, then tanning maintenance 2-3x weekly or as needed for sexual enhancement
Initial loading phase 0.25mg 1x daily
Tanning maintenance 0.5-1mg 2-3x weekly
Sexual enhancement 0.5-1mg As needed
Minimal side effects 0.1-0.25mg Every other day
Photoprotection 0.5mg 2x weekly
Side Effects
Erythropoietin (EPO)
Injection site reactions
Headache
Hypertension
Joint pain
Flu-like symptoms
Melanotan II
Nausea (pre-treatment with antiemetics recommended)
Facial flushing
Temporary blood pressure elevation
Fatigue
Spontaneous erections
Contraindications
Uncontrolled hypertension
Pure red cell aplasia history
Hemoglobin >12 g/dL (increased cardiovascular risk)
Active malignancy (relative contraindication)
History of melanoma or dysplastic nevi
Pregnancy or breastfeeding
Cardiovascular conditions
Uncontrolled hypertension
Research Evidence
Erythropoietin (EPO) Melanotan II
Status Extensively Studied Well Studied
References 4 studies 4 studies
Latest — 2024
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.